

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

**Daiichi Sankyo Announces Cooperative Sales Agreement for the
Influenza HA Vaccine “Kaketsuken”**

Tokyo, Japan (May 19, 2015) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that it has signed a cooperative sales agreement (hereinafter, The Agreement) with The Chemo-Sero-Therapeutic Research Institute (hereinafter, Kaketsuken) on May 18, 2015, for its influenza HA vaccine “Kaketsuken” (hereinafter, The Vaccine).

The Vaccine is an egg-based, inactivated vaccine used for prevention of seasonal influenza. Based on The Agreement, Daiichi Sankyo will begin sales activities of The Vaccine from next season (2015-2016).

In addition, Daiichi Sankyo will continue to sell its current influenza HA vaccine, “Kitasatodaiichisankyo”.

Daiichi Sankyo is committed to the prevention of seasonal influenza through The Vaccine, as well as to contributing to public health and preventive medicine in Japan through the provision of vaccines which fulfill unmet medical needs.

Product Overview

Name	Influenza HA vaccine “Kaketsuken”
Generic Name	Influenza HA vaccine
Classification	Biological product, powerful medicine, prescription medicine (Caution: To be prescribed by a doctor or other medical professional)
Content	Bottled 1mL: 2 bottles
Indication	Prevention of influenza
Dosage / Administration	For children age 6 months to 3 years, administer 0.25mL dose subcutaneously. For children age 3 to 13, administer two 0.5mL doses subcutaneously, with an interval of 2 to 4 weeks between administrations. For people over the age of 13, administer one 0.5mL dose or two 0.5mL doses subcutaneously with an interval of 1 to 4 weeks between administrations.
Manufacturer / Seller	The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
Seller	Daiichi Sankyo Company, Limited
Cooperative Seller	Japan Vaccine Co., Ltd.